Navigation Links
St. Jude finds molecule that could improve cancer vaccines and therapy for other diseases
Date:11/21/2007

Investigators at St. Jude Children's Research Hospital have discovered a new signaling molecule that prevents immune responses from running amok and damaging the body. The finding could lead to the development of new treatments for cancer, using vaccines; for autoimmune diseases, such as Type 1 diabetes; and for inflammatory diseases, such as inflammatory bowel disease (IBD) and asthma.

The St. Jude team discovered that specialized immune lymphocytes called regulatory T cells release a protein complex composed of two proteins called Ebi3 and Il12a. This protein complex acts like a brake on the activity of the aggressive immune cells called effector T lymphocytes. A report on this discovery appears in the journal Nature Nov. 22, 2007.

The newly recognized protein complex is one of a large group of signaling molecules called cytokines that cells use to communicate with each other. Since the immune system cytokines are called interleukins, the St. Jude team named this protein interleukin-35 (IL-35). Most cytokines stimulate immune system cells by driving the immune attack or causing inflammation. However, IL-35 is one of the few signaling molecules known to inhibit immune system activity.

The discovery of IL-35 is important because the manipulation of regulatory T cells is a key goal of immunotherapy, said Dario Vignali, Ph.D., associate member in the St. Jude Department of Immunology, and the papers senior author. Immunotherapy is the treatment of infections, cancer or other diseases by manipulating the immune system to enhance or restrict its activity. Despite the fact that regulatory T cell-mediated immunotherapy holds promise for patients, the molecules responsible for the cells ability to suppress immune system activity are largely unknown, a problem that has slowed progress in this field.

The St. Jude team showed that the genes that produce IL-35 (Ebi3 and II12a) are active in regulatory T cells but not in effector T cells and are critical to regulatory T cell function. In fact, regulatory T cells that lack the Ebi3 and II12a genes lose much of their ability to suppress effector T cells. In addition, these regulatory T cells are unable to cure mouse models of an inflammatory disease that closely resembles human IBD.

When the researchers added regulatory T cells to a culture dish with effector T cells, the regulatory T cells dramatically increased their production of the decoded forms (messenger RNA) of the Ebi3 and II12a genes. This suggests that effector T cells had released signals that stimulated the regulatory T cells to decode these genes and make IL-35, the researchers reported.

The identification of IL-35 as a key cytokine released by regulatory T cells adds significantly to our understanding of how these cells prevent immune responses from running out of control and causing damage, Vignali said. Regulatory T cells are seen as a major impediment to the development of effective anti-cancer vaccines and may prevent sterilizing immunity in certain chronic infections, such as hepatitis C and tuberculosis. As the maximal suppressive function of regulatory T cell is dependent on IL-35, blocking its activity may reduce regulatory T cell function and reduce their ability to block anti-tumor immune responses. Thus, treatments that block IL-35 activity may make anti-cancer vaccines more effective. Vaccines work by stimulating the immune system to recognize and attack specific targets, such as germs or cancer cells.

Autoimmune diseases and inflammatory diseases are caused by a breakdown of the normal regulatory processes that control our immune system, Vignali said. Novel treatments that add IL-35 or boost IL-35 activity may also provide new therapeutic opportunities for these diseases.

The identification of IL-35 is especially exciting because, to date, it is the only known cytokine that is made specifically by regulatory T lymphocytes and can suppress the activity of effector T cells directly, said Lauren Collison, Ph.D., a postdoctoral fellow in Vignalis laboratory who contributed significantly to the project. This suggests that controlling levels of IL-35 in patients might one day allow clinicians to dial the immune response up or down depending on the needs of the patient. Collison is the papers first author.


'/>"/>

Contact: Summer Freeman
summer.freeman@stjude.org
901-495-3061
St. Jude Children's Research Hospital
Source:Eurekalert

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. MRI finds breast cancer before it becomes dangerous
3. RAND finds cases of undiagnosed diabetes drop sharply
4. Children of depressed moms do better when dad is involved, SLU researcher finds
5. Ability to cope with stress can increase good cholesterol in older white men, study finds
6. Pitt study finds inequality in tobacco advertising
7. Study finds some kids are being misdiagnosed with asthma
8. Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds
9. Parents perceptions can hamper kids asthma care, study finds
10. Study finds primary care depression treatment often does not follow quality guidelines
11. Study of Studies Finds No Risk to Children From Phthalates in Toys
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... Specialty ... newly updated International Audit Protocol Consortium (IAPC) EHS audit protocol for Great ... understand the scope of their EHS regulatory obligations and rapidly collect, share, archive, ...
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... ... District , the only authorized OSHA Training Institute Education Center headquartered in Northern ... certificate program focused on providing occupational safety and health training to public sector ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... magazine’s 2017 Training Top 125 for their industry leading training methods that engage ... recognizes USA as among the global elite in employer-sponsored training and development programs. ...
(Date:12/5/2016)... , ... December 05, 2016 , ... "FCPX Overlay Glare ... but natural lighting effect without heavy rendering or complicated compositing," said Christina Austin - ... media to create an organic spectrum of lights that simulates the look of a ...
(Date:12/5/2016)... ... 05, 2016 , ... The Avamere Family of Companies will ... Transitional Care of Puget Sound ; located at 630 S Pearl Street, Tacoma, ... patients recovering from illness or injury with intensive skilled nursing and rehabilitation services. ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... Dec. 6, 2016  BioAtla, LLC, a ... of Conditionally Active Biologic (CAB) antibody therapeutics, ... Group Company, Limited (Sinobioway) selected their first ... specific program candidates and the targeted indications ... and Sinobioway entered into a strategic collaboration ...
(Date:12/6/2016)... , Dec. 6, 2016 In this age ... to be hopeful.  A special kind of sunglasses, from ... anxious life. Photo - http://photos.prnewswire.com/prnh/20161205/445444 ... Robert Buck, the psychotherapist who developed and patented the ... to overcoming anxiety and worry.  "Anxiety doesn,t have ...
(Date:12/5/2016)... Dec. 5, 2016  Zimmer Biomet Holdings, Inc. (NYSE ... pursuant to its previously-announced cash tender offers (the ... table below (collectively, the "Notes"), approximately $2.6 billion in ... and not validly withdrawn on or prior to ... time, today, December 5, 2016 (the "Early Tender ...
Breaking Medicine Technology: